TY  - BOOK
AU  - Dolman, Sarahfaye
AU  - Kolm, Paul
AU  - Weintraub, William S
TI  - Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF
SN  - 2213-1779
PY  - 2024///
KW  - IN PROCESS -- NOT YET INDEXED
KW  - Automated
KW  - MedStar Health Research Institute
KW  - Journal Article
N2  - BACKGROUND: The efficacy of sotagliflozin in patients with diabetes and recent worsening of heart failure was shown in the SOLOIST-WHF trial. However, the cost-effectiveness of sotagliflozin in these patients has not been previously investigated; CONCLUSIONS: In patients with diabetes and recent worsening of heart failure, sotagliflozin is cost-effective in the U.S. using commonly accepted willingness-to-pay thresholds. (Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure [SOLOIST-WHF]; NCT03521934). Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved; METHODS: Based on SOLOIST-WHF trial data (N = 1,222), we constructed a Markov model to estimate the lifetime impact of sotagliflozin from a U.S. health care sector perspective. Cost data were sourced from the National Inpatient Sample. Life expectancy was modeled from census data and modified by the mortality rate in SOLOIST-WHF. Fatal and nonfatal event rates were carried forward from the trial data. Utility was assessed from the published reports; OBJECTIVES: The authors sought to determine the cost-effectiveness of sotagliflozin in patients with diabetes and recent worsening of heart failure; RESULTS: Lifetime quality-adjusted life-years (QALYs) were 4.43 and 4.04 in the sotagliflozin and placebo groups, respectively, and lifetime costs were
UR  - https://dx.doi.org/10.1016/j.jchf.2024.04.018
ER  -